structural communications
Structure of triosephosphate isomerase from Cryptosporidium parvum
aSeattle Structural Genomics Center for Infectious Disease (SSGCID), USA,bDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Box 356423, Seattle, WA 98195-6423, USA,cEmerald BioStructures Inc., 7869 NE Day Road West, Bainbridge Island, WA 98110, USA, and dSeattle Biomed, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA
*Correspondence e-mail: wvanvoorhis@medicine.washington.edu
Cryptosporidium parvum is one of several Cryptosporidium spp. that cause the parasitic infection cryptosporidiosis. Cryptosporidiosis is a diarrheal infection that is spread via the fecal–oral route and is commonly caused by contaminated drinking water. Triosephosphate isomerase is an enzyme that is ubiquitous to all organisms that perform glycolysis. Triosephosphate isomerase catalyzes the formation of glyceraldehyde 3-phosphate from dihydroxyacetone phosphate, which is a critical step to ensure the maximum ATP production per glucose molecule. In this paper, the 1.55 Å resolution of the open-loop form of triosephosphate isomerase from C. parvum Iowa II is presented. An unidentified electron density was found in the active site.
Keywords: glycolysis; triosephosphate; triosephosphate isomerases; metabolism; Cryptosporidium parvum.
3D view: 3krs
PDB reference: triosephosphate isomerase, 3krs
1. Introduction
Triosephosphate isomerase (TIM) is an enzyme that is only active in its dimeric form and that has been found in almost all organisms that participate in glycolysis. The aldolase (fourth) step of glycolysis ends with two products: dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (GAP). Only GAP is able to proceed to the next phase of glycolysis. During the fifth glycolysis step, TIM catalyzes the reversible isomerization of dihydroxyacetone phosphate (DHAP) to D-glyceraldehyde 3-phosphate (GAP) (see Fig. 1). TIM is essential for maximum energy production. Because of its important role in glycolysis, triosephosphate isomerase has been described as an `an attractive target for drug design against parasites' (Mande et al., 1994).
As of January 2011, 118 structures of TIM have been released in the PDB. The first apo structure of TIM from chicken muscle was deposited in 1976 (PDB entry 1tim ; Banner et al., 1976). This was followed in 1990 by the deposition of the first ligand-bound structure of yeast TIM in the PDB [PDB entries 1ypi (Lolis et al., 1990) and 2ypi (Lolis & Petsko, 1990)]. Since then, many other TIM structures from 31 organisms, with and without ligands, have been deposited. TIM structures have been observed in both a closed and an open form. The open form has been observed for apo TIM, while ligand binding induces the closure of a loop. However, one ligand-bound structure of TIM from Plasmodium falciparum has been described with both an open and a closed conformation of the loop (Parthasarathy et al., 2003).
Cryptosporidium parvum is a protozoan parasite that causes cryptosporidiosis. Unlike the closely related C. hominis, which colonizes humans almost exclusively, C. parvum can infect a variety of vertebrates via transmission of oocytes. Together, Cryptosporidium spp. are a leading cause of morbidity and mortality in mammals, resulting primarily in gastrointestinal problems and diarrhea, or death in the immunocompromised. Currently, there are no reliable treatments for cryptosporidiosis. Paromomycin, azithromycin and nitazoxanide have all shown partial efficacy in reducing disease severity in individuals by shortening diarrheal duration (Gargala, 2008; Mead, 2002). However, for immunocompromised patients it is necessary to restore an effective in addition to antimicrobial treatment of the Cryptosporidium infection itself (Gargala, 2008). Here, we present the 1.55 Å of the apo form of TIM from C. parvum Iowa II as part of a structure-based drug-discovery effort.
2. Methods
2.1. Protein expression and purification
The gene encoding the full-length (Met1–Gln250) triosephosphate isomerase (UniProt Q5CSE7; residues 1–250) was PCR-amplified in a 96-well format using genomic DNA as the template. The primers were designed with an additional ligase-independent cloning (LIC; Aslanidis & de Jong, 1990) sequence at their 5′ ends that is complimentary to the LIC sequence in the plasmid vector. Purified PCR products were then cloned via LIC into the AVA0421 expression vector (Quartley et al., 2009), which provides a C3-cleavable hexahistidine tag at the N-terminus of the expressed protein with the sequence MAHHHHHHMGTLEAQTQ′GPGS. The recombinant plasmids were then transformed into Escherichia coli Rosetta Oxford strain [BL21*(DE3)-R3-pRARE2] cells for expression testing. Soluble protein was observed and the target was moved on to large-scale expression. The protein was given the internal designation CrpaA.01119.a.A1 and will be referred to as CrpaA.01119.a.A1/TIM.
Starter cultures of LB broth with appropriate antibiotics were grown for ∼18 h at 310 K. ZYP-5052 auto-induction medium was freshly prepared as per UW-PPG protocols (Studier, 2005; Choi et al., 2011). Antibiotics were added to 2 l bottles of sterile auto-induction medium. The bottles were inoculated with the entire overnight culture. Inoculated bottles were then placed into a LEX Bioreactor (Harbinger Biotechnology, Toronto, Ontario). Cultures were grown for ∼24 h at 298 K. The temperature was reduced to 288 K and the culture was grown for a further ∼60 h. To harvest, the medium was centrifuged at 4000g for 20 min at 277 K. The cell paste was flash-frozen in liquid nitrogen and stored at 193 K.
The frozen pellet was thawed and completely resuspended in lysis buffer (20 mM HEPES pH 7.2–7.4, 300 mM NaCl, 5% glycerol, 30 mM imidazole, 0.5% CHAPS, 10 mM MgCl2, 3 mM β-mercaptoethanol, 1.3 mg ml−1 protease-inhibitor cocktail and 0.05 mg ml−1 lysozyme). The resuspended cell pellet was then disrupted on ice for 15 min with a Branson Digital Sonifier 450D (set to 70% amplitude, with alternating cycles of 5 s pulse-on and 10 s pulse-off). The cell debris was incubated with 20 units ml−1 Benzonase nuclease (EMD, San Diego, California, USA) at room temperature for at least 40 min and clarified by centrifugation in a Sorvall RC5 (Thermo Scientific, Pittsburgh, Pennsylvania, USA) at 10 000 rev min−1 for 60 min at 277 K. The tagged TIM from C. parvum was separated from the clarified cell lysate by immobilized metal-affinity (IMAC) on a HisTrap FF 5 ml column (GE Biosciences, Piscataway, New Jersey, USA) equilibrated with binding buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM tris(2-carboxyethyl)phosphine (TCEP). The recombinant protein was eluted in 500 mM imidazole plus 1 mM TCEP. Cleavage of the N-terminal His tag was accomplished by overnight incubation with His-MBP-3C protease at 277 K while dialyzing in 25 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 1 mM TCEP, 0.025% sodium azide. The cleaved protein was recovered both in the flowthrough and in the wash fractions, utilizing the same buffers as for the initial IMAC step. After affinity-tag cleavage, a tag remnant GPGS was left at the N-terminus of the full-length protein. The protein was further resolved by size-exclusion gel (SEC; Superdex 75 26/60; GE Biosciences, Piscataway, New Jersey, USA). Pure fractions collected in SEC buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 2 mM DTT, 5% glycerol) as a single peak were analyzed using SDS–PAGE and SimplyBlue Safestain (Invitrogen, Carlsbad, California, USA). The protein was then pooled, concentrated to 75.3 mg ml−1, flash-frozen and stored at 193 K in SEC buffer. Further details can be found in Bryan et al. (2011).
2.2. Crystallization
Thawed protein was used to set up four sparse-matrix screens (JCSG+, Cryo and Wizard from Emerald BioStructures, Bainbridge Island, Washington, USA and PACT from Molecular Dimensions, Apopka, Florida, USA) following an extended Newman strategy (Newman et al., 2005). 0.4 µl protein solution was mixed with 0.4 µl well solution and equilibrated against a 100 µl reservoir using 96-well Compact Jr crystallization plates (Emerald BioStructures). Crystals suitable for diffraction studies were found in condition G8 from the PACT screen: 100 mM Bis-Tris propane pH 7.5, 200 mM sodium sulfate, 20% PEG 3350. The crystals were cryoprotected with an additional 25% ethylene glycol.
2.3. Data collection and structure determination
An X-ray diffraction data set was collected on 25 October 2009 on ALS beamline 5.0.3 at the Berkeley Center for Structural Biology, which is equipped with a 3 × 3 tiled ADSC Q315r detector. 180 images were collected at a wavelength of 0.9774 Å with a crystal-to-detector distance of 225 mm, a φ-slicing of 1° per image and an exposure time of 1 s. The diffraction data were processed with XDS/XSCALE (Kabsch, 2010; see Tables 1 and 2). The crystals belonged to P21; the diffraction limit was 1.55 Å.
|
‡Chen et al. (2010). |
Calculation of the packing density (Matthews, 1968) suggested two molecules of CrpaA.01119.a.A1/TIM per with a VM of 2.56 Å3 Da−1 and 52% solvent content. A search of the PDB for sequence homology yielded a TIM from P. falciparum (PDB entry 2vfd ; Gayathri et al., 2009) as the closest homolog, with 47% sequence identity. The search model was derived from monomer A of PDB entry 2vfd with the CCP4 program CHAINSAW (Stein, 2008; Winn et al., 2011) by trimming nonconserved amino acids to the Cγ atom while maintaining conserved residues (Schwarzenbacher et al., 2004). was performed with the CCP4 program Phaser (McCoy et al., 2007) using data between 20 and 3.5 Å resolution. The two molecules could be placed with high scores: RFZ1 = 13.4, TFZ1 = 11.8, LLG1 = 207, RFZ2 = 11.3, TFZ2 = 23.6, LLG = 797. The model was then extended by ARP/wARP (Langer et al., 2008), which built 471 residues in six chains with Rwork = 0.208 and Rfree = 0.273. The model was then iteratively extended manually using Coot (Emsley et al., 2010) followed by cycles of reciprocal-space with the CCP4 program REFMAC5 (Murshudov et al., 2011). The final model could be refined with one TLS group per chain to an Rwork of 0.157 and an Rfree of 0.188 with good stereochemistry (see Fig. 2). The model was validated with the validation tools in Coot and MolProbity (Chen et al., 2010). The final model extended from Ser2 to Gln250 in both chains. For each chain, a sodium ion was modelled binding to the carbonyl C atoms of Cys225 and Leu228 and to the hydroxyl group of Tyr5. In both σA-weighted Fo − Fc maps contoured at 3σ and σA-weighted 2Fo − Fc maps contoured at 1σ a blob of extra density could be observed in both chains in the proximity of Gly234. As neither of the components of the crystallization drop could serve as a good interpretation, this density was modelled as unidentified (UNK; see §3).
3. Results and discussion
SSGCID target CrpaA.01119.a.A1/TIM crystallized in standard sparse-matrix screens. A high-resolution data set was collected from the original screens without further optimization.
CrpaA.01119.a.A1/TIM crystallized with two monomers in the PISA (Krissinel & Henrick, 2007) confirmed that this was the native dimer. The dimer buries a surface of 1600 Å2 per monomer compared with a surface area of ∼11 000 Å2 per monomer; the free binding energy ΔGint was estimated as −96 kJ mol−1. Dimers are the active of TIMs.
Interface analysis usingThe fold of CrpaA.01119.a.A1/TIM is the typical TIM-barrel fold consisting of a barrel of eight β-strands surrounded by helices (see Fig. 2). The two monomers are very similar: 249 Cα atoms can be superimposed with an r.m.s.d. of 0.2 Å. An SSM (Krissinel & Henrick, 2004) search of the PDB reveals several other TIMs with r.m.s.d.s of around 1 Å.
Early studies on TIM revealed that the protein can exist in an open form and a closed form (Wierenga et al., 1991). The closure of a loop, commonly called `loop 6' or the `active-site loop', is typically observed in ligand-bound structures. The closed loop is thought to protect the reaction intermediates from the environment. The open conformation is typically found in apo structures. However, in P. falciparum TIM both open and closed conformations can be observed in a high-resolution (1.1 Å) ligand-bound structure (Parthasarathy et al., 2003).
In CrpaA.01119.a.A1/TIM the active-site loop extends from residues Pro168 to Ala178 and is in the open conformation (Fig. 2). While the `open' conformation is typical of apo structures, a blob of extra electron density is observed in proximity to the active site of the CrpaA.01119.a.A1/TIM structure (see Figs. 2 and 3). This blob of density almost superimposes with the phosphate group of 2-phospho-glycerate (2PG) in the TIM structure from Trypanosoma brucei (PDB entry 4tim ; Noble et al., 1991; see Fig. 3a). The two structures superimpose with an r.m.s.d. of 1.1 Å over 239 residues. Figs. 3(b) and 3(d) compare the 2PG-binding environment in T. brucei TIM with the extra blob of density in the CrpaA.01119.a.A1/TIM structure. In the T. brucei TIM structure 2PG is bound to the protein with a tight hydrogen-bond network. These interactions involve Asn11 Nδ2, His95 N∊2, Glu167 O∊1, Leu232 N (not shown in Fig. 3b), Gly234 N and Gly235 N, which are structurally conserved between the two structures. However, the extra density does not entirely match the phosphate group. Further interactions between 2PG and T. brucei TIM involve residues from the active-site loop: Gly173 N and Ser213 N. As the active-site loop in the CrpaA.01119.a.A1/TIM is in the open conformation, the latter two residues are not structurally conserved between the two structures.
In the structure of P. falciparum TIM (PDB entry 1o5x ; Parthasarathy et al., 2003) the active-site loop of subunit B is mostly in an open conformation, even though ligands are observed in the active site. In this structure, 2PG has been broken down to into two fragments, which were tentatively identified as 2-oxoglycerate and metaphosphate (see Fig. 3c). The 2-oxoglyerate group makes similar interactions with the protein as described for the T. brucei structure above. The metaphosphate occupies a similar location as the unidentified density in the CrpaA.01119.a.A1/TIM structure; however, it does not fill it entirely.
Fig. 3(d) shows a close-up of the active-site region of CrpaA.01119.a.A1/TIM and the unidentified electron density. Owing to similarity to the T. brucei and P. falciparum enzymes, a phosphate group appears to be a likely explanation for the right part of the extra electron density. With an additional water molecule on the left, the density could be fully explained. While the crystallization drop did not contain phosphate, it did contain the isosteric sulfate ion at a concentration of 200 mM. In Fig. 3(d), we have tentatively modelled a sulfate ion and an additional water molecule into the unidentified density. The somewhat tetrahedral shape of the right part of the density would support this. The sulfate group would make one direct interaction with protein (Gly235 N) and several interactions with water molecules. However, indicates that the occupancy of this sulfate would be low.
As the identity of the ligand could not be fully established, we deposited the structure with UNK atoms in the active site. Further crystallization experiments may identify the ligand and might establish the relationship between the conformation of the active-site loop and ligand binding in CrpaA.01119.a.A1/TIM.
4. Conclusions
This paper describes the purification, crystallization and structure solution of C. parvum triosephosphate isomerase (CrpaA.01119.a.A1/TIM). The presented 1.55 Å resolution structure shows the typical TIM fold and contains a dimer, which is consistent with previously observed structures. The active-site loop is in the open conformation which is typical for apo structures. An unidentified blob of electron density occupies the location of phosphate moieties of ligands in other TIM structures. However, phosphate or sulfate from the crystallization buffer can only partially explain the extra density. Additional studies would need to be performed in order to identify this ligand. Furthermore, ligand-binding studies could establish the relation between compound binding and the conformation of the active-site loop.
Acknowledgements
The authors thank the whole SSGCID team. This research was funded under Federal Contract No. HHSN272200700057C from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
References
Aslanidis, C. & de Jong, P. J. (1990). Nucleic Acids Res. 18, 6069–6074. CrossRef CAS PubMed Web of Science Google Scholar
Banner, D. W., Bloomer, A., Petsko, G. A., Phillips, D. C. & Wilson, I. A. (1976). Biochem. Biophys. Res. Commun. 72, 146–155. CrossRef CAS PubMed Google Scholar
Bryan, C. M., Bhandari, J., Napuli, A. J., Leibly, D. J., Choi, R., Kelley, A., Van Voorhis, W. C., Edwards, T. E. & Stewart, L. J. (2011). Acta Cryst. F67, 1010–1014. Web of Science CrossRef IUCr Journals Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Choi, R., Kelley, A., Leibly, D., Nakazawa Hewitt, S., Napuli, A. & Van Voorhis, W. (2011). Acta Cryst. F67, 998–1005. Web of Science CrossRef IUCr Journals Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Gargala, D. (2008). Parasite, 15, 275–281. CrossRef PubMed CAS Google Scholar
Gayathri, P., Banerjee, M., Vijayalakshmi, A., Balaram, H., Balaram, P. & Murthy, M. R. N. (2009). Acta Cryst. D65, 847–857. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Krissinel, E. & Henrick, K. (2004). Acta Cryst. D60, 2256–2268. Web of Science CrossRef CAS IUCr Journals Google Scholar
Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. Web of Science CrossRef PubMed CAS Google Scholar
Langer, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. (2008). Nature Protoc. 3, 1171–1179. Web of Science CrossRef CAS Google Scholar
Lolis, E., Alber, T., Davenport, R. C., Rose, D., Hartman, F. C. & Petsko, G. A. (1990). Biochemistry, 29, 6609–6618. CrossRef CAS PubMed Web of Science Google Scholar
Lolis, E. & Petsko, G. A. (1990). Biochemistry, 29, 6619–6625. CrossRef CAS PubMed Web of Science Google Scholar
Mande, S. C., Mainfroid, V., Kalk, K. H., Goraj, K., Martial, J. A. & Hol, W. G. (1994). Protein Sci. 3, 810–821. CrossRef CAS PubMed Google Scholar
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. CrossRef CAS PubMed Web of Science Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Mead, J. R. (2002). Drug Resist. Updat. 5, 47–57. Web of Science CrossRef PubMed CAS Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Newman, J., Egan, D., Walter, T. S., Meged, R., Berry, I., Ben Jelloul, M., Sussman, J. L., Stuart, D. I. & Perrakis, A. (2005). Acta Cryst. D61, 1426–1431. Web of Science CrossRef CAS IUCr Journals Google Scholar
Noble, M. E., Verlinde, C. L., Groendijk, H., Kalk, K. H., Wierenga, R. K. & Hol, W. G. (1991). J. Med. Chem. 34, 2709–2718. CrossRef PubMed CAS Web of Science Google Scholar
Parthasarathy, S., Eaazhisai, K., Balaram, H., Balaram, P. & Murthy, M. R. N. (2003). J. Biol. Chem. 278, 52461–52470. Web of Science CrossRef PubMed CAS Google Scholar
Quartley, E., Alexandrov, A., Mikucki, M., Buckner, F. S., Hol, W. G., DeTitta, G. T., Phizicky, E. M. & Grayhack, E. J. (2009). J. Struct. Funct. Genomics, 10, 233–247. CrossRef PubMed CAS Google Scholar
Schwarzenbacher, R., Godzik, A., Grzechnik, S. K. & Jaroszewski, L. (2004). Acta Cryst. D60, 1229–1236. Web of Science CrossRef CAS IUCr Journals Google Scholar
Stein, N. (2008). J. Appl. Cryst. 41, 641–643. Web of Science CrossRef CAS IUCr Journals Google Scholar
Studier, F. W. (2005). Protein Expr. Purif. 41, 207–234. Web of Science CrossRef PubMed CAS Google Scholar
Wierenga, R. K., Noble, M. E., Postma, J. P., Groendijk, H., Kalk, K. H., Hol, W. G. & Opperdoes, F. R. (1991). Proteins, 10, 33–49. CrossRef CAS PubMed Web of Science Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.